Skip to main content

Advertisement

SpringerLink
Log in

Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren’s syndrome

  • Case Report
  • Published:
Modern Rheumatology

Abstract

A 62-year-old woman was diagnosed with severe osteomalacia caused by renal tubular acidosis associated with Sjögren’s syndrome. She was treated with sodium bicarbonate, risedronate, alfacalcidol, and prednisolone (1 mg/kg). By 24 months, renal tubular acidosis was improved and the bone density had normalized. Here we report the successful amelioration of bone lesions through a multidisciplinary approach that improved renal tubular acidosis, with a special focus on treatment of the underlying inflammatory disorder with glucocorticoids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Fox RI. Sjögren’s syndrome. Lancet. 2005;366:321–31.

    Article  PubMed  CAS  Google Scholar 

  2. Aasarød K, Haga HJ, Berg KJ, Hammerstrøm J, Jørstad S. Renal involvement in primary Sjögren’s syndrome. QJM. 2000;93:297–304.

    Article  PubMed  Google Scholar 

  3. Pertovaara M, Korpela M, Pasternack A. Factors predictive of renal involvement in patients with primary Sjögren’s syndrome. Clin Nephrol. 2001;56:10–8.

    PubMed  CAS  Google Scholar 

  4. Bossini N, Savoldi S, Franceschini F, Mombelloni S, Baronio M, Cavazzana I, et al. Clinical and morphological features of kidney involvement in primary Sjögren’s syndrome. Nephrol Dial Transplant. 2001;16:2328–36.

    Article  PubMed  CAS  Google Scholar 

  5. Ren H, Wang WM, Chen XN, Zhang W, Pan XX, Wang XL, et al. Renal involvement and followup of 130 patients with primary Sjögren’s syndrome. J Rheumatol. 2008;35:278–84.

    PubMed  CAS  Google Scholar 

  6. Maripuri S, Grande JP, Osborn TG, Fervenza FC, Matteson EL, Donadio JV, et al. Renal involvement in primary Sjögren’s syndrome: a clinicopathologic study. Clin J Am Soc Nephrol. 2009;4:1423–31.

    Article  PubMed  Google Scholar 

  7. Lin DF, Yan SM, Zhao Y, Zhang W, Li MT, Zeng XF, et al. Clinical and prognostic characteristics of 573 cases of primary Sjögren’s syndrome. Chin Med J. 2010;123:3252–7.

    PubMed  Google Scholar 

  8. Gaarder PI, Heier HE. A human autoantibody to renal collecting duct cells associated with thyroid and gastric autoimmunity and possibly renal tubular acidosis. Clin Exp Immunol. 1983;51:29–37.

    PubMed  CAS  Google Scholar 

  9. Cohen EP, Bastani B, Cohen MR, Kolner S, Hemken P, Gluck SL. Absence of H(+)-ATPase in cortical collecting tubules of a patient with Sjogren’s syndrome and distal renal tubular acidosis. J Am Soc Nephrol. 1992;3:264–71.

    PubMed  CAS  Google Scholar 

  10. DeFranco PE, Haragsim L, Schmitz PG, Bastani B. Absence of vacuolar H(+)-ATPase pump in the collecting duct of a patient with hypokalemic distal renal tubular acidosis and Sjögren’s syndrome. J Am Soc Nephrol. 1995;6:295–301.

    PubMed  CAS  Google Scholar 

  11. Han JS, Kim GH, Kim J, Jeon US, Joo KW, Na KY, et al. Secretory-defect distal renal tubular acidosis is associated with transporter defect in H(+)-ATPase and anion exchanger-1. J Am Soc Nephrol. 2002;13:1425–32.

    Article  PubMed  CAS  Google Scholar 

  12. Takemoto F, Hoshino J, Sawa N, Tamura Y, Tagami T, Yokota M, et al. Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome. Am J Med. 2005;118:181–4.

    Article  PubMed  CAS  Google Scholar 

  13. Takemoto F, Katori H, Sawa N, Hoshino J, Suwabe T, Sogawa Y, et al. Induction of anti-carbonic-anhydrase-II antibody causes renal tubular acidosis in a mouse model of Sjogren’s syndrome. Nephron Physiol. 2007;106:63–8.

    Article  Google Scholar 

  14. Pertovaara M, Bootorabi F, Kuuslahti M, Pasternack A, Parkkila S. Novel carbonic anhydrase autoantibodies and renal manifestations in patients with primary Sjogren’s syndrome. Rheumatology. 2011;50:1453–7.

    Article  PubMed  CAS  Google Scholar 

  15. Okada M, Suzuki K, Hidaka T, Shinohara T, Kataharada K, Matsumoto M, et al. Rapid improvement of osteomalacia by treatment in a case with Sjögren’s syndrome, rheumatoid arthritis and renal tubular acidosis type 1. Intern Med. 2001;40:829–32.

    Article  PubMed  CAS  Google Scholar 

  16. Fulop M, Mackay M. Renal tubular acidosis, Sjögren syndrome, and bone disease. Arch Intern Med. 2004;164:905–9.

    Article  PubMed  Google Scholar 

  17. Arnett TR. Extracellular pH regulates bone cell function. J Nutr. 2008;138:415s–8s.

    PubMed  CAS  Google Scholar 

  18. Domrongkitchaiporn S, Pongsakul C, Stitchantrakul W, Sirikulchayanonta V, Ongphiphadhanakul B, Radinahamed P, et al. Bone mineral density and histology in distal renal tubular acidosis. Kidney Int. 2001;59:1086–93.

    Article  PubMed  CAS  Google Scholar 

  19. Domrongkitchaiporn S, Pongskul C, Sirikulchayanonta V, Stitchantrakul W, Leeprasert V, Ongphiphadhanakul B, et al. Bone histology and bone mineral density after correction of acidosis in distal renal tubular acidosis. Kidney Int. 2002;62:2160–6.

    Article  PubMed  CAS  Google Scholar 

  20. Disthabanchong S, Domrongkitchaiporn S, Sirikulchayanonta V, Stitchantrakul W, Karnsombut P, Rajatanavin R. Alteration of noncollagenous bone matrix proteins in distal renal tubular acidosis. Bone. 2004;35:604–13.

    Article  PubMed  CAS  Google Scholar 

  21. Laing CM, Unwin RJ. Renal tubular acidosis. J Nephrol. 2006;19(Suppl 9):S46–52.

    PubMed  CAS  Google Scholar 

  22. Saeki Y, Ohshima S, Ishida T, Shima Y, Umeshita-Sasai M, Nishioka K, et al. Remission of the renal involvement in a patient with primary Sjögren’s syndrome (SS) after pulse high-dose corticosteroid infusion therapy. Clin Rheumatol. 2001;20:225–8.

    Article  PubMed  CAS  Google Scholar 

  23. Miyawaki S, Nishiyama S, Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren’s syndrome. Intern Med. 1999;38:938–43.

    Article  PubMed  CAS  Google Scholar 

  24. Matsumura R, Umemiya K, Kagami M, Tomioka H, Tanabe E, Sugiyama T, et al. Glandular and extraglandular expression of the Fas–Fas ligand and apoptosis in patients with Sjogren’s syndrome. Clin Exp Rheumatol. 1998;16:561–8.

    PubMed  CAS  Google Scholar 

  25. Saoud B, Bahiri R, Benbouazza K, Bzami F, Guedira N, Hajjaj-Hassouni N. Osteomalacia revealing Sjogren’s syndrome. Joint Bone Spine. 2005;72:594–5.

    Article  PubMed  Google Scholar 

  26. Kawashima M, Amano T, Morita Y, Yamamura M, Makino H. Hypokalemic paralysis and osteomalacia secondary to renal tubular acidosis in a case with primary Sjögren’s syndrome. Mod Rheumatol. 2006;16:48–51.

    Article  PubMed  Google Scholar 

  27. Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, et al. Subcommittee to study diagnostic criteria for glucocorticoid-induced osteoporosis. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab. 2005;23:105–9.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

Yoshiya Tanaka has received consulting fees, lecture fees, and/or honoraria from Mitsubishi-Tanabe Pharma, Chugai Pharma, Eisai Pharma, Pfizer, Abbott Immunology Pharma, Daiichi-Sankyo, Janssen Pharma, Astra-Zeneca, Takeda Industrial Pharma, Astellas Pharma, Asahi-kasei Pharma, and GlaxoSmithKline, and has received research grant support from Mitsubishi-Tanabe Pharma, Bristol-Myers Squibb, Takeda Industrial Pharma, MSD, Astellas Pharma, Eisai Pharma, Chugai Pharma, Pfizer, and Daiichi-Sankyo. The other authors have declared no conflict of interest.

Author information

Authors and Affiliations

  1. The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan

    Sunao Yamamoto, Yosuke Okada, Hiroko Mori, Shintaro Hirata, Kazuyoshi Saito & Yoshiya Tanaka

  2. Inokuchi Clinic, 10-6 Yoshino-cho, Kokurakita-ku, Kitakyusyu, 802-0085, Japan

    Nobuo Inokuchi

Authors
  1. Sunao Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yosuke Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroko Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shintaro Hirata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuyoshi Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nobuo Inokuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshiya Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshiya Tanaka.

About this article

Cite this article

Yamamoto, S., Okada, Y., Mori, H. et al. Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren’s syndrome. Mod Rheumatol 23, 401–405 (2013). https://doi.org/10.1007/s10165-012-0667-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-012-0667-0

Keywords

Search

Navigation